Christina Lam,Fernando Scaglia,Gerard T Berry,Austin Larson,Kyriakie Sarafoglou,Hans C Andersson,Evgenia Sklirou,Queenie K G Tan,Rodrigo T Starosta,Mustafa Sadek,Lynne Wolfe,Seishu Horikoshi,May Ali,Rita Barone,Teresa Campbell,Irene J Chang,Kiaira Coles,Edward Cook,Erik A Eklund,Nicole M Engelhardt,Mary Freeman,Jennifer Friedman,Debbie Y T Fu,Grace Botzo,Brandy Rawls,Christien Hernandez,Christin Johnsen,Kierstin Keller,Sara Kramer,Bryce Kuschel,Angela Leshinski,Ivan Martinez-Duncker,Gina L Mazza,Saadet Mercimek-Andrews,Bradley S Miller,Karthik Muthusamy,Juanita Neira,Marc C Patterson,Natalie Pogorelc,Lex N Powers,Elizabeth Ramey,Michaela Reinhart,Audrey Squire,Jenny Thies,Jerry Vockley,Hayden Vreugdenhil,Peter Witters,Mehdi Youbi,Aziza Zeighami,Roni Zemet,Andrew C Edmondson,Eva Morava

Abstract:Objective: Our report describes clinical, genetic, and biochemical features of participants with a molecularly confirmed congenital disorder of glycosylation (CDG) enrolled in the Frontiers in Congenital Disorders of Glycosylation (FCDGC) Natural History cohort at year 5 of the study. Methods: We enrolled individuals with a known or suspected CDG into the FCDGC Natural History Study, a multicenter prospective and retrospective natural history study of all genetic causes of CDG. We conducted a cross-sectional analysis of baseline study visit data from participants with confirmed CDG who were consented into the FCDGC Natural History Study (5U54NS115198) from October 2019 to November 2023. Results: Three hundred thirty-three subjects consented to the FCDGC Natural History Study. Of these, 280 unique individuals had genetic data available that was consistent with a diagnosis of CDG. These 280 individuals were enrolled into the study between October 8, 2019 and November 29, 2023. One hundred forty-one (50.4%) were female, and 139 (49.6%) were male. Mean and median age at enrollment was 10.1 and 6.5 years, respectively, with a range of 0.22 to 71.4 years. The cohort encompassed individuals with disorders of N-linked protein glycosylation (57%), glycosylphosphatidylinositol anchor disorder (GPI anchor) (15%), disorders of Golgi homeostasis, trafficking and transport (12%), dolichol metabolism disorders (5%), disorders of multiple pathways (6%), and other (5%). The most frequent presenting symptom(s) leading to diagnosis were developmental delay/disability (77%), followed by hypotonia (56%) and feeding difficulties (42%). Mean and median time between first related symptom and diagnosis was 2.7 and 0.8 years, respectively. One hundred percent of individuals in our cohort had developmental differences/disabilities at the time of their baseline visit, followed by 97% with neurologic involvement, 91% with gastrointestinal (GI)/liver involvement, and 88% with musculoskeletal involvement. Severity of disease in individuals was scored on the Nijmegen Progression CDG Rating Scale (NPCRS) with 27% of scores categorized as mild, 44% moderate, and 29% severe. Of the individuals with N-linked protein glycosylation defects, 83% of those with data showed a type 1 pattern on carbohydrate deficient transferrin (CDT) analysis including 82/84 individuals with PMM2-CDG, 6% a type 2 pattern, 1% both type 1 and type 2 pattern and 10% a normal or nonspecific pattern. One hundred percent of individuals with Golgi homeostasis and trafficking defects with data showed a type 2 pattern on CDT analysis, while Golgi transport defect showed a type II pattern 73% of the time, a type 1 pattern for 7%, and 20% had a normal or nonspecific pattern. Most of the variants documented were classified as pathogenic or likely pathogenic using ACMG criteria. For the majority of the variants, the predicted molecular consequence was missense followed by nonsense and splice site, and the majority of the diagnoses are inherited in an autosomal recessive pattern but with disorders of all major nuclear inheritance included. Discussion: The FCDGC Natural History Study serves as an important resource to build future research studies, improve clinical care, and prepare for clinical trial readiness. Herein is the first overview of CDG participants of the FCDGC Natural History Study.

Evolutionary rate covariation is pervasive between glycosylation pathways and points to potential disease modifiers

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Identification of CNTN2 as a genetic modifier of PIGA-CDG through pedigree analysis of a family with incomplete penetrance and functional testing in Drosophila

Significantly different clinical phenotypes associated with mutations in synthesis and transamidase+remodeling glycosylphosphatidylinositol (GPI)-anchor biosynthesis genes

Glycosyltransferase genes that cause monogenic congenital disorders of glycosylation are distinct from glycosyltransferase genes associated with complex diseases

Congenital Disorders of Glycosylation from a Neurological Perspective

N-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblasts

A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG

Modeling Congenital Disorders of N-Linked Glycoprotein Glycosylation in Drosophila melanogaster

Genetic counseling for congenital disorders of glycosylation (CDG)

COG7 deficiency in Drosophila generates multifaceted developmental, behavioral and protein glycosylation phenotypes

Neuronal loss of Impairs O-glycosylation and Leads to Neurobehavioral Deficits Mimicking GALNT2-CDG

Functional Prediction of the Potential NGLY1 Mutations Associated with Rare Disease CDG

Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort

Unraveling the shared genetics of common epilepsies and general cognitive ability

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Mutations in Glycosyltransferases and Glycosidases: Implications for Associated Diseases

Developmental and Epileptic Encephalopathies: Need for Bridging the Gaps Between Clinical Syndromes and Underlying Genetic Etiologies

A pathway revisited

Biochemical diagnosis of congenital disorders of glycosylation

Serum N-glycan and O-glycan Analysis by Mass Spectrometry for Diagnosis of Congenital Disorders of Glycosylation.